Characterization of CD44 Antigen during Lymphoid Ontogeny

Collado, Antonia; Andres, Antonia de; Cañadas, E.; Ruiz‐Cabello, Francisco; Gomez, Ovidio; Pedrinaci, Susana; Garrido, Federico

doi:10.1016/s0171-2985(11)80181-6

Cited by 12 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, CD44 has been recognized as a CSC marker in several types of cancer (11). As CD44s is ubiquitously expressed in many cell types (12)(13)(14)(15)(16), its usefulness as a CSC marker may be limited. Furthermore, conflicting data in the field implicate CD44 in both tumor suppression and progression (17)(18)(19), largely attributed to the expression of alternatively spliced variants.…”

Section: Introductionmentioning

confidence: 99%

CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells

et al. 2014

View full text Add to dashboard Cite

The surface marker CD44 has been identified as one of several markers associated with cancer stem cells (CSC) in solid tumors, but its ubiquitous expression in many cell types, including hematopoietic cells, has hindered its use in targeting CSCs. In this study, 28 paired primary tumor and adjacent nontumor gastric tissue samples were analyzed for cell surface protein expression. Cells that expressed pan-CD44 were found to occur at significantly higher frequency in gastric tumor tissues. We identified CD44v8-10 as the predominant CD44 variant expressed in gastric cancer cells and verified its role as a gastric CSC marker by limiting dilution and serial transplantation assays. Parallel experiments using CD133 failed to enrich for gastric CSCs. Analyses of another 26 primary samples showed significant CD44v8-10 upregulation in gastric tumor sites. Exogenous expression of CD44v8-10 but not CD44 standard (CD44s) increased the frequency of tumor initiation in immunocompromised mice. Reciprocal silencing of total CD44 resulted in reduced tumor-initiating potential of gastric cancer cells that could be rescued by CD44v8-10 but not CD44s expression. Our findings provide important functional evidence that CD44v8-10

show abstract

Section: Introductionmentioning

confidence: 99%

CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The variant exons 6–15 can be alternatively spliced and assembled in different combinations from the standard exons to generate other variant protein isoforms (CD44v). Although CD44 has been recognized as a CSC marker in several types of cancer,19 the ubiquitous expression of CD44 in many cell type,20 reduce the usefulness of CD44s as a CSC marker. Moreover, the existence of alternatively spliced variants may be the reason for the conflicting result of CD44, which was implicated in both tumor suppression and progression 21,22.…”

Section: Discussionmentioning

confidence: 99%

Expression of Leucine-rich Repeat-containing G-protein Coupled Receptor 5 and CD44: Potential Implications for Gastric Cancer Stem Cell Marker

et al. 2016

View full text Add to dashboard Cite

BackgroundThe human leucine-rich repeat-containing G-protein coupled receptor (LGR) 5 and CD44 are one of the candidates for the marker of gastric cancer stem cells. We compared the expressions of two genes among control, dysplasia and cancer groups.MethodsWe compared the mRNA expression of LGR5, CD44 and CD44v8–10 and immunohistochemistry (IHC) of LGR5 and CD44 in gastric antral mucosa of 45 controls, 36 patients with gastric dysplasia, and 39 patients with early gastric cancer. Additionally, IHC of LGR5 in gastric body mucosa was analyzed. Normal mucosa adjacent to dysplastic or cancer lesions was used for the quantitative real-time–PCR and IHC.ResultsImmunoreactivity of LGR5 in base of antral mucosa was higher in non-cancerous tissues of cancer than those of control (P = 0.006), whereas the expression of LGR5 mRNA was not different among the three groups. Immunostaining of LGR5 was much stronger in the antrum than in the body of stomach (P < 0.001). Although there was no difference in antral immunointensity of LGR5 according to the severity of intestinal metaplasia, stronger immunostaining was found in the body with an aggravation of intestinal metaplasia (P trend < 0.001). The expression of CD44v8–10 mRNA was higher in cancer patients than control subjects and patients with dysplasia (P = 0.018 and 0.009) while the expression of CD44 mRNA was higher in the control groups than the others.ConclusionsIHC of LGR5 in crypt base and CD44 may be used for gastric CSC markers. LGR5 expression may be associated with the developing of corporal intestinal metaplasia. The expression of CD44v8–10 mRNA would be more suitable for gastric cancer stem cell marker than CD44 or LGR5 mRNA.

show abstract

Joint Features of Metastasis Formation and Lymphocyte Maturation and Activation

Zöller

1996

Attempts to Understand Metastasis Formation I

View full text Add to dashboard Cite

Characterization of CD44 Antigen during Lymphoid Ontogeny

Cited by 12 publications

References 14 publications

CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells

CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells

Expression of Leucine-rich Repeat-containing G-protein Coupled Receptor 5 and CD44: Potential Implications for Gastric Cancer Stem Cell Marker

Joint Features of Metastasis Formation and Lymphocyte Maturation and Activation

Contact Info

Product

Resources

About